SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Revenue Growth Under PressureDecelerating
Percentile Rank60
Studio
Year-over-Year Change

Year-over-year revenue growth rate

Latest
0.00%
↓ 100% vs avg
Percentile
P60
Within normal range
Average
42.44%
Historical baseline
PeriodValue
Q4 20250.00%
Q3 20250.00%
Q2 20250.00%
Q1 2025-100.00%
Q4 20240.00%
Q3 2024-100.00%
Q2 2024-72.14%
Q1 2024209.69%
Q4 2023-75.93%
Q3 20231381.56%
Q2 2023-85.28%
Q1 2023-73.11%
Q4 2022-39.80%
Q3 2022-43.47%
Q2 2022-46.20%
Q1 20226.74%
Q4 2021-24.67%
Q3 2021-19.38%
Q2 20217.57%
Q1 2021-34.27%
Q4 20200.00%